Novo Nordisk Signals Aggressive Hunt for Deals to Expand GLP-1 Pipeline
TL;DR
Novo Nordisk CEO says the company is actively pursuing acquisitions to broaden its GLP-1 pipeline amid growing competition in obesity drugs, citing assets like CagriSema and zenagamtide; Wegovy's strong Q1 performance lifted full-year guidance, even as Eli Lilly overtook Novo in weekly GLP-1 market share.
Want the full story? Read the original reporting
Read on CNBC